Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
NeoGenomics, Inc. Banner

NeoGenomics, Inc.

NEO Stock Analysis

Page title

Section title

About NeoGenomics, Inc.

Medical - Diagnostics & Research
Healthcare

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers...

NeoGenomics, Inc. Key Metrics

Market Cap
$2B
52 Weeks Low
$11.03
52 Weeks High
$21.22
P/B
2.29x
P/E
-26.65x
P/S
3.38x

Upcoming Events

    NEO Analyst Forecasts

    ‌
    ‌

    NEO Financials

    NEO Income Statement Key Metrics

    • Revenue(TTM)628.25 M
    • Gross Profit(TTM)260.96 M
    • EBITDA(TTM)-5.35 M
    • Net Income(TTM)-78.55 M
    • EPS Diluted(TTM)-0.62

    Decode NEO's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    NEO earnings and revenue history

    NEO Return on Equity

    See how efficiently NEO generates profit for it's shareholders.

    -9.34%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity Growth

    NEO's Return on Equity has shown poor growth over the past 10 years, increasing by only -17.43%.

    NEO Revenue Growth

    See how NEO has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    NEO's revenue has grown significantly over the past 10 years, increasing by over 21.12%.